

REMARKS/ARGUMENTS


Claims 18-23, 33-36 and 38-61 are pending. By this Amendment, claim 37 is cancelled, claims 18, 35 and 38 are amended, and new claims 50-61 are presented. Support for the amendments to claims 18, 35 and 38 and new claims 50-61 can be found, for example, in original claims 18, 35, 36, 38, 41 and 42. No new matter is added. In view of the foregoing amendments and following remarks, reconsideration and allowance are respectfully requested.

Rejections Under 35 U.S.C. §102


The Office Action rejects claims 18, 20-22, 33 and 34 under 35 U.S.C. §102(a) over Nakayama et al. ("A New Three-Component Photoresist Based on Calix[4]resorcinarene Derivative, a Cross-linker, and a Photo-acid Generator" (Bulletin of the Chemical Society of Japan, vol. 71, pp. 2979-2984 (1998)) (Nakayama)). Applicants respectfully traverse the rejection.

Claim 18 is set forth above. Nakayama does not disclose or suggest such a compound.

As correctly pointed out in the Office Action, Nakayama discloses the following compound:



See Office Action, pages 2 to 3; Nakayama, page 2980. However, the compound of amended claim 18 does not include the following R group:



Accordingly, Nakayama fails to disclose or suggest each and every feature of claim 18.

As explained, claim 18 is not anticipated by Nakayama. Claims 20-22, 33 and 34 depend from claim 18 and, thus, also are not anticipated by Nakayama. Accordingly, reconsideration and withdrawal of the rejection are respectfully requested.

Rejections Under 35 U.S.C. §103

A. Nakayama and Aoai

The Office Action rejects claim 19 under 35 U.S.C. §103(a) over Nakayama in view of U.S. Patent No. 5,683,856 to Aoai et al. ("Aoai"). Applicants respectfully traverse the rejection.

For the reasons discussed above, Nakayama does not disclose each and every feature of claim 18. Aoai does not remedy the deficiencies of Nakayama. Aoai is cited for its alleged disclosure of controlling impurities. *See* Office Action, page 3. However, Aoai, like Nakayama, fails to disclose or suggest a compound as recited in claim 18. Accordingly, the combination of references fails to disclose or suggest each and every feature of claim 18.

As explained, claim 18 would not have been rendered obvious by Nakayama and Aoai. Claim 19 depends from claim 18 and, thus, also would not have been rendered obvious by Nakayama and Aoai. Accordingly, reconsideration and withdrawal of the rejection are respectfully requested.

B. Nakayama and Yamada

The Office Action rejects claim 23 under 35 U.S.C. §103(a) over Nakayama in view of U.S. Patent Application Publication No. US 2003/0211421 to Yamada et al. ("Yamada"). Applicants respectfully traverse the rejection.

For the reasons discussed above, Nakayama does not disclose each and every feature of claim 18. Yamada does not remedy the deficiencies of Nakayama. Yamada is cited for its alleged disclosure of employing a quenching agent. *See* Office Action, page 4. However, Yamada, like Nakayama, fails to disclose or suggest a compound as recited in claim 18. Accordingly, the combination of references fails to disclose or suggest each and every feature of claim 18.





As explained, claim 23 would not have been rendered obvious by Nakayama and Yamada. Claim 19 depends from claim 18 and, thus, also would not have been rendered obvious by Nakayama and Yamada. Accordingly, reconsideration and withdrawal of the rejection are respectfully requested.

C. Hanabata and Yamada


The Office Action rejects claims 35 and 36 under 35 U.S.C. §103(a) over U.S. Patent Application Publication No. US 2003/0211421 to Hanabata et al. ("Hanabata") in view of U.S. Patent Application Publication No. US 2003/0099900 to Yamada et al. ("Yamada"). Applicants respectfully traverse the rejection.

Claim 35 is set forth above. Hanabata and Yamada does not disclose or suggest such a compound.

As correctly pointed out in the Office Action, Hanabata discloses the following four compounds:



See Office Action, pages 4 to 6; Hanabata, paragraphs [0211] to [0213], [0223] to [0225], [0441] to [0443] and [0611] to [0613]. In amended claim 35, A does not include:



Accordingly, Hanabata fails to disclose or suggest each and every feature of claim 35.

For the reasons discussed above, Hanabata does not disclose each and every feature of claim 35. Yamada does not remedy the deficiencies of Hanabata. Yamada is cited for its alleged disclosure of employing a quenching agent. *See Office Action*, pages 6 to 7. However, Yamada, like Hanabata, fails to disclose or suggest a compound as recited in claim 35. Accordingly, the combination of references fails to disclose or suggest each and every feature of claim 35.

As explained, claim 35 would not have been rendered obvious by Hanabata and Yamada. Claim 36 depends from claim 35 and, thus, also would not have been rendered obvious by Hanabata and Yamada. Accordingly, reconsideration and withdrawal of the rejection are respectfully requested.

D. Hanabata, Yamada and Aoai

The Office Action rejects claim 42 under 35 U.S.C. §103(a) over Hanabata in view of Yamada and Aoai. Applicants respectfully traverse the rejection.

For the reasons discussed above, Hanabata and Yamada does not disclose each and every feature of claim 35. Aoai does not remedy the deficiencies of Hanabata and Yamada. Aoai is cited for its alleged disclosure of controlling impurities. *See Office Action*, pages 7 to 8. However, Aoai, like Hanabata and Yamada, fails to disclose or suggest a compound as recited in claim 18. Accordingly, the combination of references fails to disclose or suggest each and every feature of claim 35.


As explained, claim 35 would not have been rendered obvious by Ito and Aoai. Claim 42 depends from claim 35 and, thus, also would not have been rendered obvious by Ito and Aoai. Accordingly, reconsideration and withdrawal of the rejection are respectfully requested.

E. Aoso


The Office Action rejects claims 35-41 under 35 U.S.C. §103(a) over JP 2002-229193 to Aoso ("Aoso"). By this Amendment, claim 37 is cancelled, rendering the rejection moot as to that claims. As to the remaining claims, Applicants respectfully traverse the rejection.

Claims 35 and 38 are set forth above. Aoso does not disclose or suggest such compounds.


Aoso discloses the following two compounds:



and



See Aoso, paragraphs [0070] to [0083]. However, in amended claim 35, A does not include:



Likewise, in amended claim 38, B, C and D do not include a t-butyloxycarbonyl methyl group. Accordingly, Aoso fails to disclose or suggest each and every feature of claims 35 and 38.

As explained, claims 35 and 38 would not have been rendered obvious by Aoso. Claims 36 and 39-41 depend from claims 35 and 38 and, thus, also would not have been rendered obvious by Aoso. Accordingly, reconsideration and withdrawal of the rejection are respectfully requested.

F. Aoso and Aoai

The Office Action rejects claim 42 under 35 U.S.C. §103(a) over Aoso in view of Aoai. Applicants respectfully traverse the rejection.

For the reasons discussed above, Aoso does not disclose each and every feature of claim 35. Aoai does not remedy the deficiencies of Aoso. Aoai is cited for its alleged disclosure of controlling impurities. *See* Office Action, pages 9 to 10. However, Aoai, like Aoso, fails to disclose or suggest a compound as recited in claim 35. Accordingly, the combination of references fails to disclose or suggest each and every feature of claim 35.

As explained, claim 35 would not have been rendered obvious by Aoso and Aoai. Claim 42 depends from claim 35 and, thus, also would not have been rendered obvious by Aoso and Aoai. Accordingly, reconsideration and withdrawal of the rejection are respectfully requested.

Double Patenting

The Office Action provisionally rejects claims 35-49 under the judicially created doctrine of obviousness-type double patenting over claims 4-6 and 25 of U.S. Patent Application No. 10/531,208 in view of U.S. Patent Application Publication No. US


Application No. 10/594,282
Reply to Office Action of June 1, 2009

2003/0008232 to Kinsho et al. Applicants respectfully request that the rejection be held in abeyance until the 208 application issues as a patent or the present application is indicated to be otherwise in condition for allowance.

New Claims


By this Amendment, new claims 50-61 are presented.

New claim 50 correspond to original claim 35, wherein A is limited to




and B, C and D do not include a tert-butyloxycarbonyl group. In new claim 50, B, C and D do not include a t-butyloxycarbonyl group. Accordingly, new claim 50 is believed to distinguish over Hanabata. New claims 51-53 depend from claim 50 and, thus, are also believed to be patentable over Hanabata.

New claim 54 corresponds to original claim 35, wherein A is limited to



and R does not include a tert-butyloxycarbonyl group or a 1-ethoxyethyl group. In new claim 54, R does not include a t-butyloxycarbonyl group or a 1-ethoxyethyl group. Accordingly, new claim 54 is believed to distinguish over Hanabata. New claims 55-57 depend from claim 54 and, thus, are also believed to be patentable over Hanabata.

New claim 58 corresponds to original claim 35, wherein A is limited to



and the tert-butyloxycarbonylmethyl group of B, C and D is deleted. In new claim 58, B, C and D do not include a t-butyloxycarbonyl methyl group. Accordingly, new claim 58 is believed to distinguish over Aoso. New claims 59-61 depend from claim 58 and, thus, are also believed to be patentable over Aoso.

Accordingly, new claims 50-61 are believed to distinguish over the references of record.

Conclusion

For the foregoing reasons, Applicants submit that claims 18-23, 33-36 and 38-61 are in condition for allowance. Prompt reconsideration and allowance are respectfully requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon

Jacob A. Doughty
Registration No. 46,671

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 08/07)